Phenotypes associated with this allele
mortality/aging
|
|
• expected numbers of homozygotes are found at E12.5, but complete lethality is observed by E13.5
|
embryo
|
|
• at E12.5, mutants are growth retarded
|
|
|
• no hematopoiesis is visible in the yolk sac or embryo at E12.5
|
growth/size/body
|
|
• at E12.5, mutants are growth retarded
|
hematopoietic system
|
|
• no hematopoiesis is visible in the yolk sac or embryo at E12.5
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sox17tm2Sjm mutation
(1 available);
any
Sox17 mutation
(28 available)
Tg(Pdx1-cre)6Tuv mutation
(3 available)
|
|
|
endocrine/exocrine glands
|
|
• embryos show varying degrees of shortening of the cystic duct
|
|
|
• embryos exhibit biliary atresia-like phenotypes such as epithelial deciduation and bile duct stenosis/atresia
|
|
|
• epithelial deciduation in the gallbladder
|
|
|
• embryos show varying degrees of shortening of the gallbladder
|
immune system
|
|
• hepatitis in fetuses with normal or mild gallbladder abnormalities but not hepatitis in fetuses with complete lack of the gallbladder
|
liver/biliary system
|
|
• embryos show varying degrees of shortening of the cystic duct
|
|
|
• embryos exhibit biliary atresia-like phenotypes such as epithelial deciduation and bile duct stenosis/atresia
|
|
|
• epithelial deciduation in the gallbladder
|
|
|
• embryos show varying degrees of shortening of the gallbladder
|
|
|
• hepatitis in fetuses with normal or mild gallbladder abnormalities but not hepatitis in fetuses with complete lack of the gallbladder
|
|
|
• 4/55 embryos exhibit severe gross hepatic lesions
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Sox17tm2Sjm mutation
(1 available);
any
Sox17 mutation
(28 available)
Tg(Cdh5-cre/ERT2)1Rha mutation
(3 available)
|
|
|
cardiovascular system
|
|
• under prolonged angiotensin II (AT II) infusion, tamoxifen treated mice show luminal dilation, wall thinning, and decreased vascular smooth muscle layers at multiple vascular locations around the distal intracerebral bifurcation of intracerebral arteries
• under AT II infusion, endothelial junctions of intracerebral arteries from tamoxifen treated mice are severely disrupted
• under AT II infusion, intracerebral arteries from tamoxifen treated mice show infrequent focal endothelial denudation
|
|
|
• under moderate AT II infusion, abdominal aorta of tamoxifen treated mice shows a modest decrease in wall thickness but does not show luminal dilation
|
|
|
• under moderate AT II infusion, thoracic aorta of tamoxifen treated mice shows a modest decrease in wall thickness but does not show luminal dilation
|
|
|
• tamoxifen treated mice under AT II infusion occasionally exhibit arterial dissection on the walls of intracranial arteries
|
|
|
• under AT II infusion, endothelial layers in vessels of tamoxifen treated mice exhibit an abnormal lateral morphology with an irregular and flattened shape
|
|
|
• arteries from tamoxifen treated mice have less coverage by vascular smooth muscle cells
|
|
|
• about 25% of tamoxifen treated mice show abnormally enlarged structure with tortuosity resembling fusiform dilation or a balloon-like structure indicative of saccular aneurysm
• 60% of tamoxifen treated mice subjected to a moderate hypertensive condition by infusion with a low dose of angiotensin II (AT II) exhibit features of intracranial aneurysm, showing vascular enlargement of intracerebral arteries, luminal dilation, and wall thinning
|
|
|
• tamoxifen treated mice under AT II infusion frequently exhibit hemorrhage in cerebrospinal fluid, in the intracranial region, and in the intramural region
• hemorrhage is infrequently seen in mutants under steady state conditions
|
|
|
• under AT II infusion, intracerebral arteries from tamoxifen treated mice show increased stress-induced leakage of intravenously infused Evans blue dye
|
cellular
|
|
• AT II-induced endothelial proliferation is suppressed in the vessels of tamoxifen treated mice
|
muscle
|
|
• arteries from tamoxifen treated mice have less coverage by vascular smooth muscle cells
|
mortality/aging
|
|
• death of all mice by 14 days after birth
|
hematopoietic system
|
|
• mice display severe reduction in thymus cellularity upon examination at 4-5 days after end of poly(I:C) treatment
|
|
|
• when sacrificed 4-5 days after end of poly(I:C) treatment, reduced bone marrow cellularity is observed
|
|
|
• numbers are significantly reduce compared to controls following cre induction
|
|
|
• numbers are significantly reduce compared to controls following cre induction
|
|
|
• HSCs are reduced in bone marrow and spleen
|
|
|
• when sacrificed 4-5 days after end of poly(I:C) treatment, reduced spleen cellularity is observed
|
immune system
|
|
• mice display severe reduction in thymus cellularity upon examination at 4-5 days after end of poly(I:C) treatment
|
|
|
• numbers are significantly reduce compared to controls following cre induction
|
|
|
• when sacrificed 4-5 days after end of poly(I:C) treatment, reduced spleen cellularity is observed
|
endocrine/exocrine glands
|
|
• mice display severe reduction in thymus cellularity upon examination at 4-5 days after end of poly(I:C) treatment
|
Analysis Tools